Harvard Bioscience slumps after weak revenue forecast
** Shares of Harvard Bioscience HBIO.O down 12.1% at 67 cents premarket ** Co expects Q1 revenue between $19 million and $21 million, below analysts' estimates of $22.95 million - data compiled by LSEG ** The company is also exploring alternative capital sources for refinancing outstanding indebtedness by June 30 ** As of last close, HBIO down ~64% YTD (Reporting by Pritam Biswas in Bengaluru) ((Pritam.Biswas@thomsonreuters.com))
Recent news on Harvard Bioscience
See all newsBrief: Harvard Bioscience Announces Creation Of Scientific Advisory Board
Harvard Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary
Harvard Bioscience Q2 revenue rises on telemetry demand, lifts 2026 outlook
Harvard Bioscience Inc expected to post a loss of 21 cents a share - Earnings Preview
Harvard Bioscience Q1 revenue falls, reaffirms 2026 guidance